Pyrimidine derivatives as PI3K inhibitors
US8252792B2 · kind B2 · utility
0Cited by
1References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 25, 2007 |
| Grant date | Aug 28, 2012 |
| Priority date | — |
| Expiry date | Dec 11, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Thienopyrimidines of formula (Ia) or (Ib):wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.